New Delhi

TLM Shahdara Hospital

Shahdara is a part of the National Capital Territory (NCT) of Delhi, which is one of the fastest growing agglomerations in the world. Around 40% of the population lives in slums and temporary hutments with no proper address (permanency). They are exposed to harsh weather conditions like extreme heat, heavy rains, and bone chilling winter. Night shelters are scarce, leading to spread of communicable diseases. Infrastructure, such as housing, is poor. Basic amenities, such as safe drinking water, hygiene, and nutritious food are scarce.


TLM Shahdara Hospital was established in the year 1984.

The Leprosy Mission Trust India started the hospital in 1984 as a leprosy control unit. Later, it was developed into a tertiary leprosy care hospital. Thereafter, it was transformed into a full-fledged community hospital, treating people with all kinds of diseases and disabilities. It caters to the urban population around Shahdara, where there are a number of leprosy colonies.

The facilities provided by the hospital include consulting rooms, in-patient rooms, operating theatre, laboratory services, ECG services, X-ray services, counselling, physiotherapy, pharmacy, MCR protective footwear and artificial limbs.

Goal of the hospital

The goal of the hospital is to address the physical, mental and social problems of people affected by leprosy in the north-east district of Delhi.

The hospital aims to achieve this through:

  • Raising awareness about leprosy in the communities for early self-reporting
  • Facilitating urban leprosy control activities under government’s National Leprosy Eradication Programme (NLEP) in the North East Delhi.
  • Enhancing the capacity of community-based organisations (CBOs) to promote social integration and equality among people affected by disability caused by leprosy.
  • Promoting self-reliance among persons with disabilities, leprosy affected and other marginalised sections of the community.



Outpatient Inpatient
The hospital provides holistic care for the following specialities:

  • leprosy treatment and management
  • dermatology
  • general medicine
  • general physiotherapy
  • general surgery
  • ophthalmology
  • reconstructive surgery

In 2015, 76,000 general consultations were provided, with:

  • 5% leprosy
  • 83% dermatology
  • 53% general medicine
The hospital has a 45-bedded in-patient wing and provides best inpatient facility with 24-hour nursing care and latest equipment. In 2015, patients were admitted as follows:

  • 620 for leprosy (eye care, ulcer, surgery, lepra reaction and neuritis, etc).
  • 300 for general medicine.

About 11,000 leprosy bed days and 430 general patient bed days were utilised.



Support services (lab tests; X-ray, ECG, physiotherapy, counselling):

  • 36,000 lab tests, including 1,700 skin smear examinations for leprosy, 18,000 haematology tests and 13,000 biochemistry tests done in 2015.
  • 570 X-ray examinations and 160 ECGs done.
  • 1,600 patients underwent
  • 1,800 leprosy patients counselled.

Prevention of impairment and disability (POID) in leprosy:

The hospital provides patient education, physiotherapy, pre-fabricated splints, MCR protective footwear, etc, to leprosy patients to prevent impairment and disability.
In 2015:

In 2015:

  • 150 leprosy patients diagnosed with reaction/neuritis were given appropriate treatment.
  • 50 ulcer surgeries done.
  • The hospital has an MCR protective footwear manufacturing unit which manufactured 130 pairs and supplied to hospital patients and to the government.
  • The hospital supplied 110 orthoses to leprosy patients, manufactured in its artificial limbs manufacturing unit.

Community outreach:

The hospital has a community outreach programme in schools and tribal villages. It networks with the government and other NGOs for implementing its community development programmes. More than 600 people affected by leprosy were supported in accessing government social welfare schemes for education, economic development, healthcare, housing, insurance, livelihood pension, etc.